Insights from the DEVOTE Trial with Insulin Degludec

Duration

< 15 mins

Profession

Allied Health

Physician

Nursing

Specialist

Pharmacy

Student

Medical Resident

# of Credits

0.0

Accreditation

N/A

Expiry Date

2020-07-30

The DEVOTE study demonstrated that insulin degludec is associated with less severe daytime hypoglycemia and nocturnal hypoglycemia when used in patients with type 2 diabetes at high risk of cardiovascular events. The findings of this study can have important implications for the selection of insulin treatment in patients with type 2 diabetes.

Unaccredited

Vincent Woo, MD, FRCPC

Gihane Zarifa, MD



Related Courses